Proton Beam Therapy for Ameloblastic Carcinoma of the Maxilla: Report of a Rare Case by 山縣 憲司 et al.
Proton Beam Therapy for Ameloblastic Carcinoma
of the Maxilla: Report of a Rare Case
著者（英） Kenji YAMAGATA, Hitoshi ISHIKAWA, Takashi
Saito, Hiroki BUKAWA
journal or
publication title
Journal of oral and maxillofacial surgery
volume 77
number 1
page range 227.e1-227.e5
year 2019-01
権利 (C) 2018. This manuscript version is made
available under the CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4
.0/
URL http://hdl.handle.net/2241/00154966
doi: 10.1016/j.joms.2018.08.014
Creative Commons : 表示 - 非営利 - 改変禁止
http://creativecommons.org/licenses/by-nc-nd/3.0/deed.ja
1 
Proton beam therapy for ameloblastic carcinoma of the maxilla: 
report of a rare case  
Kenji Yamagata1, DDS, PhD, Hitoshi Ishikawa2, MD, PhD, Takashi Saito3, MD, 
Hiroki Bukawa4 MD, DDS, PhD 
1 Assistant Professor, Department of Oral and Maxillofacial Surgery, Institute of 
Clinical medicine, Faculty of medicine, University of Tsukuba 
2 Professor, Department of Radiation Oncology, Institute of Clinical medicine, 
Faculty of medicine, University of Tsukuba  
3 Resident, Department of Radiation Oncology, Institute of Clinical medicine, Faculty 
of medicine, University of Tsukuba  
4 Professor, Department of Oral and Maxillofacial Surgery, Institute of Clinical 
medicine, Faculty of medicine, University of Tsukuba 
Correspondence: Kenji Yamagata, Department of Oral and Maxillofacial Surgery, 
Institute of Clinical medicine, Faculty of medicine, University of Tsukuba, 
1-1-1 Tenodai, Tsukuba, Ibaraki 305-8575, Japan
y-kenji@md.tsukauba.ac.jp
2 
Abstract 
Ameloblastic carcinoma (AC) is a rare malignant odontogenic tumor that combines 
the histological features of ameloblastoma with cytological atypia. The standard 
treatment for this lesion is wide local excision. Proton beam therapy (PBT), which 
can deliver high irradiation doses to target while avoiding irradiation to surrounding 
normal tissues but no reports of PBT for AC have been published so far. We here 
report a case of a 70-year-old Japanese woman with a pathological diagnosis of 
maxillary AC who refused surgical resection, and received hypofractionated PBT at 
a total dose of 69 Gy in 23 fractions. She is still alive for more than 5 years after PBT 
without any evidences of recurrence and side effects. This is the first successful 
treatment case after curative radiation therapy for maxillary AC. 
Key words: Ameloblastic carcinoma (AC), Maxilla, Proton beam therapy (PBT) 
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Introduction 
Ameloblastic carcinoma (AC) is a rare malignant odontogenic tumor, with 
fewer than 200 reported cases.1  AC combines the histological features of 
ameloblastoma with cytological atypia regardless of whether it has metastasized. 
The standard treatment for the disease is wide local excision with cervical lymph-
node dissection, but efficacy of radiotherapy (RT) or chemotherapy seems to be 
limited.2  There are a few case reports treated with RT using gamma-ray, X-ray, 
and carbon-ions,3-6 but there are no reports of proton beam therapy (PBT) for AC. 
The main role of RT is an adjuvant or salvage treatment after surgery. Patients 
treated with conventional external beam radiation have been reported to have long 
term control more than 10 years out with relatively few side effects. Here we firstly 
report a successful treatment by PBT for a case with AC of the maxilla.   
Case Report 
A 70-year-old Japanese woman was referred to our department in 2012. She 
had complained of a tumor at her left maxillary gingiva 2 months before. Uterine 
fibroids and goiter were recorded as her medical history Examination of the oral 
cavity revealed a soft elastic mass measuring approximately 20 x 15 mm adjacent to 
the left molar region of the maxilla (Fig 1), but she did not complained of trismus. 
T2- weighted magnetic resonance images (MRI) showed a 43 x 22 x 21 mm high 
intensity tumor which was located at the posterior of the maxillary sinus and 
extended to the pterygomaxillary fossa. There was no cervical lymph-node 
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metastasis. (Fig 2). A biopsy from the maxillary gingiva under local anesthesia was 
performed and histopathologically, basal-cell-like tumor-cell growth, irregular nests, 
and peripheral tumor-cell nests with penetrating palisades were observed. Inside 
the nest, the tumor-cell density was low, and the tumor cells exhibited pleomorphism 
and a stellate reticulum-like structure. The mitotic figures differed in size and had 
moderate to severe nuclear atypia. Nuclear mitosis was frequently observed (>10/10 
HPF). Based on these histopathological findings, her tumor was confirmed as AC 
finally (Fig 3).  
Cancer board recommended curative surgical resection of her tumor, but she 
refused to receive it and wanted to receive definitive RT as an alternative 
treatment. Radiation oncologists explained both characteristics of photon RT and 
PBT, and she selected PBT for the treatment. Hypofractionated PBT at a total PBT 
dose of 69 Gy in 23 fractions with a fractional dose of 3 Gy over 5 weeks, equivalent 
to 74.5 Gy with a conventional fraction dose of 2 Gy when using the linear-
quadratic model (α/β=10), was perfomed. PBT was planned using a three-
dimensional planning system based on CT images with a 5-mm slice thickness. The 
patient was immobilized in a supine position, under a thermoplastic mask. The 
initial clinical target volume (CVT) included a visible tumor with 10 mm margins 
for all directions  and left maxillary sinus, but PBT fields were shrunken three 
times step by step (Fig 4).   
Treatment was uneventful except for grade 2 dermatitis and stomatitis that 
occurred with 40 Gy. Five years after PBT, the patient is still alive with neither any 
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recurrence nor any side effects. MRIs depict a slight hypertrophy of the sinus 
mucosa that has unchanged for five years since PBT (Fig 5). She continues to 
receive followed up examinations. 
Discussion 
AC was systematically reviewed by Saluja et al. (153 cases). 1  The 2005 World 
Health Organization (WHO) classification divides AC into primary type; secondary 
type, intraosseous; and secondary type, peripheral. Most AC appears to arise de novo, 
but a few cases were reported to arise from preexisting ameloblastoma. Although our 
case was consistent with primary type AC, this subclassification may be 
unnecessarily complex for an already rare lesion, and the 2017 WHO classification 
lists a single diagnostic entity of AC but acknowledges varied histological features. 7 
AC has different clinical features in the maxilla and in the mandible, and has a lower 
incidence in the maxilla than in the mandible.8  Maxillary AC lesions appear to 
occur slightly later in life (average age 56.7 years) than in the mandible.9 Although 
AC lesions tend toward aggressive local growth and local relapse, distant metastases 
are uncommon.10  In our case, the patient was older than the average age in 
previously reported cases, and the AC did not exhibit aggressive growth and relapse, 
fortunately.  
When AC arises de novo, diagnosis can be difficult because it must be 
differentiated from primary intraosseous squamous cell carcinoma, metastatic 
carcinoma of the jaw, and central high-grade mucoepidermoid carcinoma. Therefore, 
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findings of typical histological features of ameloblastoma, such as peripheral 
palisading, reverse polarity, and a stellate reticulum-like structure, provide clues to 
a diagnosis of AC.11 Although our case arose de novo, the diagnosis was not 
particularly difficult because of the peripheral palisading, stellate reticulum-like 
structure, and frequent nuclear mitosis observed. 
The most favorable treatment for AC is thought to be early surgical 
management with or without RT or chemotherapy, determined by the site and extent 
of the tumor,1 because it produced the highest mean survival time (140 months, 95% 
CI 106–174), compared to RT (17.5 months, 95% CI 2.95–32.1) and chemotherapy (8 
months, 95% CI 8–8).1  The main role of RT is an adjuvant or salvage treatment 
after surgery,2 patients treated with postoperative conventional RT who have a long-
term local control more than 10 years with relative few late sequelae.12  On the 
other hand, outcomes of non-conventional RT for each two cases with recurrences or 
residual tumors after surgery were reported as case presentations (Table 1). Jensen 
et al. reported a successful case with recurrent AC treated with carbon-ion therapy 
for recurrent AC, but a follow-up period was very short (3 months).4 Perera et al. 
reported the use of gamma-knife stereotactic radiosurgery for AC,3 with a survival 
of 2.5 years from treatment without disease at the treated site. Helical tomotherapy, 
a unique intensity-modulated radiotherapy delivery system, was performed for two 
cases of AC for the postoperative treatment of residual tumors.5, 6 The four cases 
were treated with miscellaneous dose fractionation schedules at different total doses 
ranging from 16 to 60 Gy, and followed for 3 to 30 months. In our case, a prescribed 
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PBT dose was initially set at 60 Gy in 20 fractions, but the a visible tumor remained 
on CT images at time after 51 Gy. Therefore, we decided to add a boost PBT of 9 Gy 
in 3 fractions using shrunken fields covering only tumors without any margins (Fig 
4). This is the first report showing a successful case treated with definitive RT as 
initial treatment, and she has been followed up for the longest period (more than 5 
years) without any recurrences. Furthermore, no severe acute or late complications 
were observed, fortunately. The result suggests that PBT has a possibility to manage 
AC patients who are regarded as not only medically inoperable but also suitable for 
curative surgery. Further experience may show the efficacy of PBT for AC patients 
in the future. 
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FIGURE 1. Examination of the oral cavity 
Intraoral examination revealed a soft elastic mass measuring approximately 20 x 
15 mm in the posterior left molar of the maxilla. 
FIGURE 2. MRI findings 
(A) Axial T2-weighted (T2WI) and (B) coronal STIR scans, depicting a 43 x 22 x 21
mm mass with high signal intensity. The mass was located at the posterior of the 
maxillary sinus and extended to the pterygomaxillary fossa. 
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Figure 3. Pathological findings 
HE-stained tissue at (A) low and (B) high power magnification. The basal cell-like 
tumor-cell growth showed irregular nests and peripheral tumor cells of penetrating 
palisade nests. A follicular-growth pattern was observed with stellate reticulum-
like tumor cells. The mitotic figures were different in size and showed moderate to 
severe nuclear atypia, with frequent nuclear mitosis (>10/10 HPF). 
FIGURE 4. Proton-beam therapy dose distribution of 69 Gy/23 Fr (equivalent dose: 
74.5 Gy) 
(A1) Initial treatment plan (Axial), (A2)Initial treatment plan (Lateral) 
(B1) Final (4th) treatment plan(Axial), (B2)Final (4th) treatment plan(Lateral) 
Figure 5. Follow-up MRI 5 years after proton therapy 
(A) Axial T2WI and (B) coronal STIR MR images showed a slight hypertrophy of
the sinus mucosa, which did not change during the 5-year follow-up period. 
Table. 1 Reported non-conventional RT treatments for AC 
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TABLE 1.  Reported non-conventional RT treatments for AC 
No Author 
(year) 
Patient Treatment Dose Prognosis Duration 
1 Jensen et 
al. (2011) 
71/M Carbon ion 
therapy 
60GyE/20fr Alive 3 months 
2 Perera et al. 
(2013)   
35/M Gamma knife 
stereotactic 
radiosurgery 
16Gy/1fr Death 
from 
cancer 
2.5 years 
3 Koca et al. 
(2014) 
35/M Helical 
tomotherapy 
60Gy Alive 1 year 
4 Takahashi 
et al. (2016) 
58/M Helical 
tomotherapy 
25Gy/1fr Alive 19months 
5 Our case 
(2018)   
70/F Proton 
therapy 
69Gy/23fr Alive 5 years 
